In vivo modulation of plasma Free Fatty Acids in patients with Familial Combined Hyperlipidemia using Lipid-Lowering medication

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 4, 2002, Pages 1576-1580

  Meijssen, S ^a   Derksen, R J ^a   Bilecen, S ^a   Erkelens, D W ^a   Castro Cabezas, M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CATECHOLAMINE; ENZYME INHIBITOR; FATTY ACID; FIBRIC ACID DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FAMILIAL HYPERLIPEMIA; FATTY ACID BLOOD LEVEL; FEMALE; HORMONE SENSITIVITY; HUMAN; INSULIN RESISTANCE; MALE; MENTAL STRESS; PRIORITY JOURNAL;

EID: 0036281385     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.4.8408     Document Type: Article

References (32)

1. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia
2. Familial combined hyperlipidaemia: 1973-1991
3. Family study of serum lipids and lipoproteins in coronary heart-disease
4. Inheritance of combined hyperlipoproteinemia: Evidence for a new lipoprotein phenotype
5. Impaired response of fibroblasts from patients with hyperapobetallpoproteinemia to acylation-stimulating protein
6. The adipocyte, fatty acid trapping, and atherogenesis
7. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance
8. Insulin resistance in patients with familial combined hyperlipidemia and coronary artery disease
9. Glucose intolerance in familial combined hyperlipidaemia
10. Impaired free fatty acid suppression during hyperinsulinemia is a characteristic finding in familial combined hyperlipidemia, but insulin resistance is observed only in hypertriglyceridemic patients
11. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia
12. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: A precursor defect for dyslipidemia?
13. Adipose tissue lipoprotein lipase and hormone-sensitive lipase. Contrasting findings in familial combined hyperlipidemia and insulin resistance syndrome
14. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia
15. Adipocyte metabolism in adipocyte fatty acid binding protein knockout (aP2-/-) mice after short term high-fat feeding: Functional compensation by the keratinocyte fatty acid binding protein
16. Localization of adipocyte long-chain fatty acyl-CoA synthase at the plasma membrane
17. Insulin mediated inhibition of hormone sensitive lipase activity in vivo in relation to endogenous catecholamines in healthy subjects
18. Prevention of in vitro lipolysis by tetrahydrolipstatin
19. Proteolysis of human apolipoprotein B: Effect on quantitative immtmoturbidimetry
20. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
21. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia
22. Reduced hormone-sensitive lipase activity is not a major metabolic defect in Finnish FCHL families
23. Effects of insulin on fatty acid reesterification in healthy subjects
24. Molecular mechanisms for hormonal control of adipose tissue lipolysis
25. Effects of physiological hypercortisolemia on the regulation of lipolysis in subcutaneous adipose tissue
26. No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families
27. Non-esterified fatty acid metabolism and postprandial lipaemia
28. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period
29. Acylation stimulating protein (ASP), an adipocyte autocrine: New directions
30. Plasma acylation stimulating protein (ASP) as a predictor of impaired cellular biological response to ASP in patients with hyperapoB
31. The pathogenetic role of impaired fatty acid trapping by adipocytes in generating the pleiotropic features of hyperapoB
32. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease. Effects of expanded dose simvastatin